MGMT Promoter Methylation: Prognostication beyond Treatment Response.

Autor:	Ashkan K; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Baig Mirza A; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Soumpasis C; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Syrris C; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Kalaitzoglou D; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Sharma C; GKT School of Medicine, Kings College London, London SE1 1UL, UK., James ZJ; GKT School of Medicine, Kings College London, London SE1 1UL, UK., Khoja AK; GKT School of Medicine, Kings College London, London SE1 1UL, UK., Ahmed R; GKT School of Medicine, Kings College London, London SE1 1UL, UK., Vastani A; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Bartram J; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Chia K; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Al-Salihi O; Department of Neuro-Oncology, Cancer Centre, Guys Hospital, Great Maze Pond, London SE1 9RT, UK., Swampilai A; Department of Neuro-Oncology, Cancer Centre, Guys Hospital, Great Maze Pond, London SE1 9RT, UK., Brazil L; Department of Neuro-Oncology, Cancer Centre, Guys Hospital, Great Maze Pond, London SE1 9RT, UK., Laxton R; Department of Neuropathology, Kings College London, London SE5 9RS, UK., Reisz Z; Department of Neuropathology, Kings College London, London SE5 9RS, UK., Bodi I; Department of Neuropathology, Kings College London, London SE5 9RS, UK., King A; Department of Neuropathology, Kings College London, London SE5 9RS, UK., Gullan R; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Vergani F; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Bhangoo R; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Al-Sarraj S; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK., Lavrador JP; Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.
Jazyk:	angličtina
Zdroj:	Journal of personalized medicine [J Pers Med] 2023 Jun 14; Vol. 13 (6). Date of Electronic Publication: 2023 Jun 14.
DOI:	10.3390/jpm13060999
Abstrakt:	MGMT promoter methylation is related to the increased sensitivity of tumour tissue to chemotherapy with temozolomide (TMZ) and thus to improved patient survival. However, it is unclear how the extent of MGMT promoter methylation affects outcomes. In our study, a single-centre retrospective study, we explore the impact of MGMT promoter methylation in patients with glioblastoma who were operated upon with 5-ALA. Demographic, clinical and histology data, and survival rates were assessed. A total of 69 patients formed the study group (mean age 53.75 ± 15.51 years old). Positive 5-ALA fluorescence was noted in 79.41%. A higher percentage of MGMT promoter methylation was related to lower preoperative tumour volume ( p = 0.003), a lower likelihood of 5-ALA positive fluorescence ( p = 0.041) and a larger extent of resection EoR ( p = 0.041). A higher MGMT promoter methylation rate was also related to improved progression-free survival (PFS) and overall survival (OS) ( p = 0.008 and p = 0.006, respectively), even when adjusted for the extent of resection ( p = 0.034 and p = 0.042, respectively). A higher number of adjuvant chemotherapy cycles was also related to longer PFS and OS ( p = 0.049 and p = 0.030, respectively). Therefore, this study suggests MGMT promoter methylation should be considered as a continuous variable. It is a prognostic factor that goes beyond sensitivity to chemotherapy treatment, as a higher percentage of methylation is related not only to increased EoR and increased PFS and OS, but also to lower tumour volume at presentation and a lower likelihood of 5-ALA fluorescence intraoperatively. Competing Interests: The authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu